Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 202

1.

Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study.

Skoog Ståhlgren G, Tyrstrup M, Edlund C, Giske CG, Mölstad S, Norman C, Rystedt K, Sundvall PD, Hedin K.

BMJ. 2019 Oct 4;367:l5337. doi: 10.1136/bmj.l5337.

2.

Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up.

Eliassen KE, Reiso H, Berild D, Lindbæk M.

Clin Microbiol Infect. 2018 Dec;24(12):1290-1296. doi: 10.1016/j.cmi.2018.02.028. Epub 2018 Mar 2.

PMID:
29505880
3.

Does macrolide use confer risk of out-of-hospital cardiac arrest compared with penicillin V? A Danish national case-crossover and case-time-control study.

Hertz FB, Jensen A, Knudsen JD, Arpi M, Andersson C, Gislason GH, Køber L, Torp-Pedersen C, Lippert F, Weeke PE.

BMJ Open. 2018 Feb 23;8(2):e019997. doi: 10.1136/bmjopen-2017-019997.

4.

The Penicillin for the Emergency Department Outpatient treatment of CELLulitis (PEDOCELL) trial: update to the study protocol and detailed statistical analysis plan (SAP).

Boland F, Quirke M, Gannon B, Plunkett S, Hayden J, McCourt J, O'Sullivan R, Eustace J, Deasy C, Wakai A.

Trials. 2017 Aug 24;18(1):391. doi: 10.1186/s13063-017-2121-2.

5.

Interventions for the prevention of recurrent erysipelas and cellulitis.

Dalal A, Eskin-Schwartz M, Mimouni D, Ray S, Days W, Hodak E, Leibovici L, Paul M.

Cochrane Database Syst Rev. 2017 Jun 20;6:CD009758. doi: 10.1002/14651858.CD009758.pub2. Review.

6.

Low-dose penicillin in early life induces long-term changes in murine gut microbiota, brain cytokines and behavior.

Leclercq S, Mian FM, Stanisz AM, Bindels LB, Cambier E, Ben-Amram H, Koren O, Forsythe P, Bienenstock J.

Nat Commun. 2017 Apr 4;8:15062. doi: 10.1038/ncomms15062.

7.

Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice.

Livanos AE, Greiner TU, Vangay P, Pathmasiri W, Stewart D, McRitchie S, Li H, Chung J, Sohn J, Kim S, Gao Z, Barber C, Kim J, Ng S, Rogers AB, Sumner S, Zhang XS, Cadwell K, Knights D, Alekseyenko A, Bäckhed F, Blaser MJ.

Nat Microbiol. 2016 Aug 22;1(11):16140. doi: 10.1038/nmicrobiol.2016.140.

8.

Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study.

Inghammar M, Svanström H, Melbye M, Pasternak B, Hviid A.

BMJ. 2016 Feb 26;352:i843. doi: 10.1136/bmj.i843.

9.

Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study.

Svanström H, Pasternak B, Hviid A.

BMJ. 2014 Aug 19;349:g4930. doi: 10.1136/bmj.g4930.

10.

Cardiovascular risks with azithromycin.

Mosholder AD, Nambiar S.

N Engl J Med. 2013 Aug 8;369(6):581. doi: 10.1056/NEJMc1306999. No abstract available.

PMID:
23930274
11.

Cardiovascular risks with azithromycin.

Brass EP.

N Engl J Med. 2013 Aug 8;369(6):580. doi: 10.1056/NEJMc1306999. No abstract available.

PMID:
23924018
12.

Cardiovascular risks with azithromycin.

McMurray JJ, Jhund PS.

N Engl J Med. 2013 Aug 8;369(6):579-80. doi: 10.1056/NEJMc1306999. No abstract available.

PMID:
23924017
13.

Cardiovascular risks with azithromycin.

Svanström H, Pasternak B, Hviid A.

N Engl J Med. 2013 Aug 8;369(6):580-1. doi: 10.1056/NEJMc1306999. No abstract available.

PMID:
23924016
14.

Azithromycin erhöht--zumindest bei jüngeren menschen--die kardiovaskuläre mortalität nicht.

Steurer J.

Praxis (Bern 1994). 2013 Aug 7;102(16):1010. doi: 10.1024/1661-8157/a001385. German. No abstract available.

PMID:
23919943
16.

Use of azithromycin and death from cardiovascular causes.

Svanström H, Pasternak B, Hviid A.

N Engl J Med. 2013 May 2;368(18):1704-12. doi: 10.1056/NEJMoa1300799.

17.

Cardiovascular risks with azithromycin and other antibacterial drugs.

Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S.

N Engl J Med. 2013 May 2;368(18):1665-8. doi: 10.1056/NEJMp1302726. No abstract available.

18.

Evaluation of the sensitizing potential of antibiotics in vitro using the human cell lines THP-1 and MUTZ-LC and primary monocyte-derived dendritic cells.

Sebastian K, Ott H, Zwadlo-Klarwasser G, Skazik-Voogt C, Marquardt Y, Czaja K, Merk HF, Baron JM.

Toxicol Appl Pharmacol. 2012 Aug 1;262(3):283-92. doi: 10.1016/j.taap.2012.04.038. Epub 2012 May 18.

PMID:
22609641
19.

Penicillin V-induced drug rash with eosinophilia and systemic symptoms.

Orbak Z, Sepetcigil O, Karakelleoğlu C, Gülses S.

West Indian Med J. 2010 Dec;59(6):722-5.

PMID:
21702250
20.

Drug rash with eosinophilia and systemic symptoms after penicillin V administration in a patient with acquired C1 inhibitor acquired deficiency.

Doña I, Chaves P, Gómez E, Torres MJ, Cantó LG, Blanca M.

J Investig Allergol Clin Immunol. 2009;19(4):325-7. No abstract available.

Supplemental Content

Loading ...
Support Center